These findings underscore the crucial role of CXCL9 in enhancing the efficacy of ICB treatments for preclinical OC and suggest that CXCL9 inducers could serve as both a viable predictive biomarker and a potent co-administration partner for improving ICB effectiveness in this cancer type (174). Here, CXCL9 is linked to cancer.